Thursday, November 12, 2015
The EMA has recommended granting a marketing authorization, following Accelerated Assessment, for Praxbind (idarucizumab) as a specific antidote to the anticoagulant medicine Pradaxa (dabigatran etexilate), when rapid reversal of its effect is required. Praxbind is to be used when a patient taking Pradaxa needs to undergo an emergency surgery or when life-threatening or uncontrolled bleeding occurs.
Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors.
Hikma Pharmaceuticals, a multinational pharmaceutical group, has agreed to acquire Boehringer Ingelheim Roxane and Roxane Laboratories from Boehringer Ingelheim. Roxane is a well-established U.S. specialty generics company with a highly differentiated product portfolio and best-in-class R&D capabilities.